Research programme: FASN inhibitors - 3-V Biosciences

Drug Profile

Research programme: FASN inhibitors - 3-V Biosciences

Alternative Names: TVB 3664

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator 3-V Biosciences
  • Class Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Parainfluenza virus infections; Solid tumours
  • No development reported Hepatitis C; Herpes simplex virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top